Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | GUSB | P08236 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3844287 | 0.79 | RAB9A (0.47) | — | |
| Bromide SCHEMBL3849745 | 0.79 | ATM (0.52) | HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL3848623 | 0.78 | POLB (0.53) | — | |
| Bromide SCHEMBL3850362 | 0.75 | POLB (0.42) | CES2CES1 | |
| Bromide SCHEMBL3845562 | 0.75 | CES2 (0.36) | CES2CES1 | |
| Hydrochloric Acid SCHEMBL3851951 | 0.73 | CES2 (0.41) | CTSDGUSBCES2CES1HTR2A | |
| Bromide SCHEMBL3853756 | 0.72 | NPC1 (0.45) | CTSD | |
| Bromide SCHEMBL3844954 | 0.72 | RAB9A (0.51) | — | |
| Bromide SCHEMBL3845433 | 0.71 | CTNNB1 (0.41) | — | |
| Hydrochloric Acid SCHEMBL3846574 | 0.70 | GFER (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7432254-B2 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | SYNVISTA THERAPEUTICS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-7166625-B2 | Method for treating fibrotic diseases and other indications | ALTEON, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | SYNVISTA THERAPEUTICS, INC. | 2004-11-25 | — | — | US | disclosed |
| US-20030176426-A1 | Method for treating fibrotic diseases or other indications with imidazolium agents | ALTEON, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | SYNVISTA THERAPEUTICS, INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020160993-A1 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | ALTEON, INC. | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | MMP1, COL1A1, COL2A1 | CTSD 807/4885GUSB 60/4885CES2 854/4885 |
| US-20020160993-A1 | Method for treating glaucoma IC | CHAT, MYOC, GAP43 | CTSD 3580/4885GUSB 465/4885CES2 3399/4885 |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | MMP1, COL1A1, COL2A1 | CTSD 830/4885GUSB 80/4885CES2 781/4885 |
| US-20030176426-A1 | Method for treating fibrotic diseases or other indications with imidazolium agents | MMP1, COL1A1, COL2A1 | CTSD 1924/4885GUSB 1088/4885CES2 776/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | CTSD 1342/4885GUSB 264/4885CES2 1305/4885 |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | MMP1, COL1A1, COL2A1 | CTSD 720/4885GUSB 63/4885CES2 1244/4885 |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | MMP1, COL1A1, EPX | CTSD 2080/4885GUSB 1584/4885CES2 1014/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | CTSD 2393/4885GUSB 266/4885CES2 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.